KEY vs SKYE · P/E 13, rev $7.51B vs $25.0M cap
KeyCorp (KEY) versus Skye Bioscience, Inc. Common Stock (SKYE) — a side-by-side from cached financials, not a winner call.
KeyCorp (KEY) is a banks - regional company listed on US.
Skye Bioscience, Inc. Common Stock (SKYE) is a biotechnology company listed on NASDAQ.
Latest reported KEY revenue for 2025-12-31 was $7.51B. Net income was $1.83B. Revenue was up 62.7% from 2024-12-31 to 2025-12-31. KEY currently screens at market cap $22.64B and trailing P/E 12.8.
SKYE does not have a complete income-statement cache yet.
KEY currently screens at market cap $22.64B and trailing P/E 12.8. SKYE currently screens at market cap $25.0M.
Not investment advice. Open the KEY and SKYE stock pages for the full models.
Not investment advice.